Histologically or cytologically proven advanced (stage IIIB/IV) NSCLC subjects who are immunotherapy naïve.
Participants with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy
Histologically confirmed or cytologically confirmed diagnosis of stage IV NSCLC
Histologically or cytologically confirmed Stage IIIb or IV breast cancer with cutaneous metastases.
Histologically or cytologically confirmed advanced (stage IIIB or IV) NSCLC
Have previously untreated, histologically confirmed NSCLC and histologically confirmed Stage IIB or IIIA NSCLC.
Patient must have histologically or cytologically confirmed metastatic or recurrent NSCLC which is progressing.
Histologically or cytologically confirmed diagnosis of NSCLC that carries an ALK rearrangement
Histologically or cytologically confirmed non-squamous NSCLC
Histologically confirmed non-squamous NSCLC, with incurable advanced or metastatic disease
Have a histologically confirmed diagnosis of NSCLC
Patients with histologically or cytologically confirmed stage IV NSCLC not amendable to curative surgery or radiation
Histologically cytologically confirmed NSCLC
Histologically or cytologically confirmed diagnosis of NSCLC that is:
Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC.
Histologically confirmed diagnosis of NSCLC
Have histologically- or cytologically-confirmed diagnosis of Stage IV NSCLC and meet the corresponding requirements for the cohort of the study they will enroll into;
Cytologically or histologically confirmed non squamous NSCLC Stage IV (including pleural effusion).
Histologically or cytologically confirmed diagnosis of Stage IV non-squamous NSCLC.
Patients with histologically or cytologically documented squamous or non-squamous NSCLC with stage IIIB or stage IV disease, who received no prior systemic treatment for recurrent or metastatic NSCLC
A histologically or cytologically confirmed diagnosis of stage IV NSCLC
Subject has definitive histologically or cytologically confirmed Stage IIIB or IV NSCLC.
Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC
Subjects with histologically or cytologically confirmed NSCLC:
Has a histologically-confirmed or cytologically confirmed diagnosis of stage IV nonsquamous NSCLC.
Histologically confirmed locally advanced or stage IV NSCLC
Have histologically or cytologically confirmed stage IIIB (and not a candidate for definitive multimodality therapy) or stage IV NSCLC.
Histologically or cytologically documented diagnosis of NSCLC
Histologically or cytologically confirmed Stage IIIB-IVB NSCLC
Have histologically or cytologically confirmed squamous NSCLC.
Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC
Histologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del).
Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test
Histologically confirmed advanced (Stage IIIB/IV) NSCLC (all histologies including squamous and sarcomatoid)
Subject must have cytologically or histologically confirmed advanced or metastatic non-squamous NSCLC and are current or former smokers.
Subjects with histologically or cytologically documented NSCLC.
Subject must have cytologically or histologically confirmed squamous NSCLC.
Histologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic anticancer therapy
Histologically or cytologically documented NSCLC
Histologically-  or cytologically-confirmed, treatment naive (or status post treatment regimens of tyrosine kinase inhibitor and/or immunotherapy) stage IV non-squamous, NSCLC
histologically or cytologically proven diagnosis of malignancy other than NSCLC
Histologically or cytologically confirmed NSCLC
Histologically or cytologically confirmed stage IIIB or IV NSCLC with non-squamous histology
Histologically or cytologically confirmed squamous or non-squamous NSCLC
Must have histologically or cytologically confirmed non-squamous NSCLC.
Histologically confirmed squamous advanced NSCLC (Stage IV).
Has a histologically and/or cytologically confirmed diagnosis of NSCLC (squamous or nonsquamous).
Histologically or cytologically confirmed diagnosis of NSCLC that is Stage IIIb, IV, or recurrent.
Stage IV, histologically or cytologically confirmed NSCLC; confirmation may be obtained with the first protocol-specified tumor biopsy
Must have cytologically or histologically confirmed NSCLC with either:
Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy).
Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC
Have a histologically or cytologically confirmed diagnosis of stage IV NSCLC.
Histologically or cytologically confirmed Stage IV non-squamous NSCLC
Histologically or cytologically confirmed Stage IV squamous NSCLC
Histologically or cytologically confirmed Stage IIIB or IV advanced or metastatic NSCLC with measurable neoplastic disease. Sputum cytology alone is not considered an acceptable method of diagnosis;
Diagnosis of NSCLC, histologically or cytologically confirmed
Histologically or cytologically confirmed unresectable NSCLC
Histologically or cytologically confirmed incurable Stage IIIb/IV NSCLC tumor
Histologically or cytologically confirmed non-squamous NSCLC
Histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC
Patients with stage IV or recurrent/metastatic histologically or cytologically confirmed non-squamous NSCLC
Subjects with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy
Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC
Histologically or cytologically confirmed metastatic NSCLC including recurrent disease
